The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements with AstraZeneca (AZ, NASDAQ: AZN), Tigermed (SHE: 300347), Simcere (HKG: 2096), and a total of 20 other companies. This initiative is set to generate cumulative investments of HKD 30 billion (approximately USD 3.83 billion) in the region, creating tens of thousands of job opportunities and enhancing the local economy.
Sirnaomics and Key Corporation Offices
Among the notable participants is Sirnaomics Ltd (HKG: 2257), a Sino-US siRNA therapy developer, along with its subsidiary RNAimmune and partner EDIRNA. These companies are the first to formalize agreements with the government, focusing on establishing key corporation offices aimed at strengthening Hong Kong’s innovation and technology ecosystem.
Fostering Innovation Across Multiple Sectors
The introduction of these key corporation offices, as outlined in the Policy Address of October 2022, encompasses various sectors including life sciences and health technology, artificial intelligence and data science, financial technology, advanced manufacturing, new materials, and new energy technology. This strategic move is expected to catalyze growth and innovation across multiple industries in Hong Kong.-Fineline Info & Tech
